NCT03418324View on ClinicalTrials.gov

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

November 6, 2019

Study Completion Date

November 6, 2019

Conditions
Prostate Cancer
Interventions
DRUG

TRC105

Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks

DRUG

Abiraterone

Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.

DRUG

Enzalutamide

Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.

Trial Locations (1)

90048

Cedars Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

Cedars-Sinai Medical Center

OTHER

NCT03418324 - Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy | Biotech Hunter | Biotech Hunter